The Shenderov Lab focuses on the elucidation of the mechanisms of immune response and resistance to immunotherapy in Prostate Cancer. This has led to clinical and basic research investigating the presumptive checkpoint inhibitor B7-H3. In pursuit of understanding biomarkers or resistance and response, and regulatory molecules of immune response, we utilize artificial intelligence, immunogenomics, and spatial proteomics and transcriptomics in the laboratory and at the bedside using clinical trial correlative samples.

Directed by Debraj “Raj” Mukherjee, MD, MPH, the laboratory focuses on improving access to care, reducing disparities, maximizing surgical outcomes, and optimizing quality of life for patients with brain and skull base tumors.

The laboratory achieves these aims by creating and analyzing institutional and national databases, developing and validating novel patient-centered quality of life instruments, leveraging machine learning and artificial intelligence platforms to risk-stratify vulnerable patient populations, and designing novel surgical trials to push the boundaries of neurosurgical innovation.

Our research also investigates novel approaches to improve neurosurgical medical education including studying the utility of video-based surgical coaching and the design of new operative instrumentation.

Andreia Faria's Laboratory focuses on investigating brain functions using MRIs. We develop and apply methods for processing and analyzing diverse MRI modalities in order to characterize distinctive brain patterns and to study multiple conditions, including neurodegenerative diseases, psychiatric disorders, and stroke. We use artificial intelligence to develop tools for brain MRI segmentation and quantification, promoting the means to perform reliable and reproducible translational research.

The Johns Hopkins Laboratory of Computational Intensive Care Medicine (LCICM) has been established to gain knowledge on the mechanisms of critical illness and injury, with the aim of identifying novel methods to treat patients admitted to the intensive care unit (ICU). Members of the lab apply mathematical and statistical models, artificial intelligence, and domain expertise to unravel patterns in data from sources such as electronic health records, high-frequency physiological recordings, and medical imaging. These patterns are resolved into health signatures that can be leveraged for classification and prediction. The overarching goal is to enhance the precision, efficacy, and outcomes of care delivered to critically ill patients.

The Abadir Lab focuses on uncovering the molecular mechanisms underlying frailty, resilience, and age-related diseases to bridge the gap between basic science and clinical applications. Grounded in translational research, the lab investigates the intricate interplay between mitochondrial biology, the renin-angiotensin system (RAS), and chronic inflammation, with an emphasis on their roles in physical and cognitive decline.

Key Areas of Research

1. Mitochondrial and Angiotensin Biology
   • Discovery and exploration of the mitochondrial angiotensin system (MAS) as a critical regulator of cellular energy, inflammation, and resilience.
   • Investigating age-related mitochondrial dysfunction and its contribution to frailty, chronic inflammation, and neurodegeneration.
2. Biomarker Development
   • Identification of novel biomarkers for aging-related frailty and resilience, including cell-free DNA fragments and kynurenine metabolites.
   • Development of diagnostic tools for early detection of physical and cognitive decline.
3. Innovative Therapeutics and Bioengineering
   • Designing nano-delivery systems for targeted drug delivery to mitochondria, enhancing wound healing and reversing cellular senescence.
   • Integration of artificial intelligence and engineering to create advanced diagnostic tools for assessing frailty and aging-related conditions.
4. AI and Technology in Aging
   • Leveraging artificial intelligence and bioengineering to address challenges in geriatric medicine through collaborations with the Johns Hopkins AI & Technology Collaboratory for Aging Research (AITC) and the Gerotech Incubator Program.

Our Approach

The Abadir Lab employs a multidisciplinary methodology, combining molecular biology, bioinformatics, and engineering to tackle the pressing health challenges of aging populations. By fostering collaboration between clinicians, scientists, and engineers, the lab ensures that discoveries translate into tangible benefits for older adults.

Translational Impact

With a focus on frailty, inflammation, and cognitive decline, the Abadir Lab contributes to the development of personalized interventions and precision medicine approaches. Our work has laid the foundation for:

• Repurposing drugs like losartan and valsartan for treating aging-related chronic wounds.
• Unveiling the role of mitochondrial dysregulation in Alzheimer’s disease and frailty.
• Innovating tools for clinical assessments of resilience and functional decline.

Collaborations and Mentorship

The Abadir Lab is committed to training the next generation of scientists, fostering an interdisciplinary environment where students and postdocs explore cutting-edge aging science. Collaborations with the Johns Hopkins GeroTech Incubator Program and the Translational Aging Research Training Program (T32) further enrich this ecosystem of innovation.

Join Us

Whether you're a researcher, student, or collaborator, the Abadir Lab welcomes individuals passionate about transforming aging research into clinical practice.

The Mathioudakis lab is focused on developing and evaluating clinical decision support systems, technology, and mHealth for diabetes prevention and management. Our lab leverages large electronic medical record databases and uses machine learning algorithms and artificial intelligence to identify patterns in clinical care associated with optimal clinical outcomes. We are interested in understanding the role that advanced diabetes technologies can play in improving health outcomes for patients with diabetes. Our lab has published extensively on outcomes related to diabetes prevention and diabetes management and outcomes. Based on data from our long-term (over 10 year) clinic-based prospective cohort study from the Johns Hopkins Multidisciplinary Diabetic Foot and Wound Clinic, we have published extensively on clinical predictors and outcomes of patients with diabetic foot ulcers, focusing specifically on the role that glycemic control plays in patients with this complication. Healthcare disparities exist throughout medicine, but are particularly prominent in diabetes; our lab has evaluated healthcare inequities in diabetes outcomes and is developing and evaluating strategies to overcome them. In addition to identify optimal management approach to diabetes and its complications, our lab is interested in development and evaluation of innovative technology approaches to diabetes prevention.